Eylea vs. Eylea HD: What’s the Difference?
Eylea and Eylea HD at a Glance
Both are shots given into the eye. Most visits are calm and dull, which is what you want. But a few signs mean you should call your eye doctor the same day. These signs can be the first hint of an infection inside the eye, a torn or detached retina, or a jump in eye pressure. The drug labels tell patients to report them without delay12
- Severe eye pain, or pain that gets worse after the first day
- A sudden drop in vision, or a new curtain or shadow across your sight
- A shower of new floaters, or new flashing lights
- A red and painful eye, with new light sensitivity
- Thick discharge, or a lid that swells shut
Now the calming part. A serious infection inside the eye is rare. A large US claims study counted it after 136 of 135,973 aflibercept shots, or about 1 in every 1,0003 A Korean hospital database counted fewer than 1 case in every 10,000 aflibercept shots4 Caught early, it is far easier to treat. So one phone call, the same day, is the whole job.
They are the same drug. Eylea and Eylea HD both contain aflibercept. Both are given as an injection into the jelly at the back of the eye21 They work the same way, they are given at the same kind of office visit, and they carry the same short list of warnings. Both share the same three reasons a doctor will not inject on a given day: an infection in or around the eye, active inflammation inside the eye, or a known allergy to aflibercept12 If you have had one, the other will feel familiar.
Eylea HD is a stronger dose of the same medicine. It is built to buy you longer gaps between shots. Eylea delivers 2 mg of aflibercept in 0.05 mL of liquid2 Eylea HD delivers 8 mg in 0.07 mL. That is four times the drug in a slightly larger drop1 The point of the higher dose is not sharper vision. It is fewer trips to the clinic for a similar result.
Your retina specialist does, with you. The American Academy of Ophthalmology's practice pattern says the choice of biologic product, whether the reference drug, a biosimilar, or an interchangeable one, should be that of the treating ophthalmologist and the patient whenever possible5 The decision usually turns on four things: which eye condition you have, how your eye has responded so far, how hard it is for you to get to appointments, and what your insurance covers. None of that can be settled from a web page, including this one.
What Each Medicine Is and Which Eye Problems It Treats
Eylea HD is the higher strength version of the same drug. It is aflibercept 8 mg in 0.07 mL. Eylea HD is FDA-approved for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema after a retinal vein occlusion1 The letters HD stand for high dose. They do not mean high definition, and they are not a promise about how sharp your vision will be.
They switch off a growth signal that is causing trouble at the back of your eye. In wet macular degeneration and in diabetic eye disease, the retina releases a growth protein (clinical: vascular endothelial growth factor, or VEGF). It tells fragile new blood vessels to grow and leak. Aflibercept works as a decoy. Both drug labels describe it binding VEGF-A and a related growth factor, so those signals cannot switch on their receptors21 Anti-VEGF injections are the most common treatment doctors use to slow vision loss from wet AMD, and they help stop bleeding and leaking from blood vessels at the back of your eye6 A Cochrane review of 16 trials in 6,347 people found anti-VEGF treatment holds vision steady, and improves it in some eyes7
Their approved lists overlap almost completely. There is one real gap. Macular edema is swelling in part of the retina, its most common cause is diabetic retinopathy, and blocked retinal veins are among the other causes8 Both aflibercept strengths cover wet AMD, diabetic macular edema, diabetic retinopathy, and macular edema after a vein occlusion12 Only the 2 mg Eylea is approved for retinopathy of prematurity, at a much smaller 0.4 mg dose2 A premature baby is not a candidate for the HD version.
Eylea vs. Eylea HD Side by Side
The schedules are where the two really part ways. Both start with monthly loading doses. Eylea then settles at every 8 weeks for wet AMD, diabetic macular edema and diabetic retinopathy21 Eylea HD can be stretched to every 8 to 16 weeks for wet AMD and diabetic macular edema, and every 8 to 12 weeks for diabetic retinopathy1 Vein occlusion is the sharpest contrast of all.
| What differs | Eylea (2 mg) | Eylea HD (8 mg) |
|---|---|---|
| Drug per shot | 2 mg | 8 mg |
| Liquid per shot | 0.05 mL | 0.07 mL |
| Loading doses | 3 monthly (5 for diabetic eye disease) | 3 monthly (3 to 5 for vein occlusion) |
| Wet AMD after loading | Every 8 weeks | Every 8 to 16 weeks |
| Diabetic macular edema | Every 8 weeks | Every 8 to 16 weeks |
| Diabetic retinopathy | Every 8 weeks | Every 8 to 12 weeks |
| Vein occlusion | Every 4 weeks | Every 8 weeks after loading |
Here is the same picture for the conditions themselves. The uses below come straight from the two FDA-approved labels for aflibercept21
| Condition | Eylea (2 mg) | Eylea HD (8 mg) |
|---|---|---|
| Wet AMD | Approved | Approved |
| Diabetic macular edema | Approved | Approved |
| Diabetic retinopathy | Approved | Approved |
| Macular edema after vein occlusion | Approved | Approved |
| Retinopathy of prematurity | Approved | Not approved |
The trials were built to show the higher dose was not worse. They were not built to show it was better. In PULSAR, 1,009 adults with wet AMD gained on average 6.7 letters on the 8 mg dose every 12 weeks and 6.2 letters every 16 weeks, against 7.6 letters on the 2 mg dose every 8 weeks at one year. That sat inside the trial's 4-letter margin9 In PHOTON, 658 adults with diabetic macular edema gained 8.8 and 7.9 letters on the two 8 mg schedules, against 9.2 letters on the 2 mg schedule10 Read those numbers as a tie, reached with fewer needles.
| Trial (condition) | Eylea HD groups at 1 year | Eylea group at 1 year |
|---|---|---|
| PULSAR (wet AMD) | +6.7 letters every 12 weeks; +6.2 letters every 16 weeks | +7.6 letters every 8 weeks |
| PHOTON (diabetic macular edema) | +8.8 letters every 12 weeks; +7.9 letters every 16 weeks | +9.2 letters every 8 weeks |
Both are reasonable, and the tiebreaker is usually your life rather than your retina. Eylea HD tends to appeal when travel to the clinic is hard, when you rely on someone else to drive, or when the appointment treadmill is the part you dread. In PULSAR, 1,011 people were randomised, and at 48 weeks the 8 mg groups on 12-week and 16-week gaps gained about as much vision as the 2 mg group on 8-week gaps9 Eylea tends to stay in place when your eye is already steady on it, when the patient is a premature baby, or when a lower-cost biosimilar matters to your budget.
What an Injection Visit Is Actually Like
Less than you fear, and it is over quickly. Your doctor numbs the eye and cleans it with antiseptic to lower the chance of infection, then gives the medicine through a very small needle11 You are awake. You are asked to look in one direction, and a small holder keeps your eyelid open so you cannot blink on the needle. Most people describe pressure rather than pain.
Expect a gritty, scratchy eye and a few odd visual effects. Irritation from the antiseptic is common, and some people see floating air bubbles that look like floaters11 A red patch on the white of the eye (clinical: conjunctival hemorrhage) is first on the Eylea label's list of the most common reactions, those reported in 5 percent or more of patients2 What should not happen is pain that climbs, or vision that gets worse instead of better. That is the same-day phone call described at the top of this page.
Most people pick up their day where they left off. The National Eye Institute notes that most people can go back to normal activities right away after an anti-VEGF injection, and that the injection does not change vision straight away11 Ask your clinic whether to bring a driver, because vision can be blurry afterwards from the antiseptic and any dilating drops. Plan a quiet evening and do not rub the eye.
Risks, Side Effects, and a Realistic Outlook
The frequent ones are local, mild and short. For Eylea, reactions reported in at least 5 of every 100 patients were bleeding on the white of the eye, eye pain, cataract, vitreous detachment, floaters, and raised eye pressure2 The Eylea HD label reports a similar set at a lower cut-off, of at least 3 of every 100 patients, and also names a surface scratch on the cornea, blurred vision, and retinal bleeding1 The two lists use different reporting cut-offs, so they are not a like-for-like ranking of which drug causes more. None of these is a reason to skip treatment, and each is worth mentioning at your next visit.
The serious risks are shared by both strengths, and they are uncommon. Both labels carry warnings for infection inside the eye, retinal detachment, retinal vasculitis, and a rise in eye pressure12 Both labels also state that there is a potential risk of arterial thromboembolic events, meaning clot-related events such as stroke or heart attack, following intravitreal use of VEGF inhibitors21 Set beside the numbers earlier on this page, this is a small risk carried many times rather than a large one carried once. That is why the same-day warning signs are worth learning.
Some situations rule out an injection that day, or for good. Neither strength should be given when there is an infection in or around the eye, when there is active inflammation inside the eye, or when the patient is allergic to aflibercept21 A stye, a bad case of pink eye, or a recent flare of inflammation inside the eye (clinical: uveitis) will usually get your appointment moved rather than cancelled. Tell the clinic before you travel in, not after you arrive.
These are averages across large groups. Your own eye may do better or worse. Across PULSAR and PHOTON, average vision at one year improved by roughly 6 to 9 letters on an eye chart on both strengths910 Eye side effects in the treated eye were similar between strengths, at about 39 of every 100 people in PULSAR and 28 to 32 of every 100 in PHOTON910 No one can tell you in advance what your own letters will do. For many people the honest goal is holding on to the vision they have.
Money is a real part of this decision. Pavblu, an aflibercept biosimilar to Eylea, is supplied at 2 mg in 0.05 mL, the Eylea strength rather than the 8 mg strength12 Any biosimilar option therefore applies to the 2 mg side of this comparison, not the HD side. Whether that saves you anything depends on your plan, so ask the clinic's billing staff to run both options against your coverage before you decide.
When to Call Your Retina Specialist
Call the retina practice that gave the injection, not a general helpline. Say when your shot was and describe what changed. At night or on a weekend, use the after-hours number on your discharge sheet. Go to an emergency room if you cannot reach anyone and your eye is painful or your vision is dropping. The National Eye Institute advises contacting your eye doctor right away when pain or vision problems get worse after an injection, because these can be signs of infection11
Plenty of what you notice afterwards is expected. A scratchy, dry feeling from the antiseptic, a small red patch on the white of the eye, and a few extra floaters are all among the commonly reported reactions after these injections112 Mention them at your next appointment. The dividing line is direction of travel. Symptoms that fade day by day are routine. Symptoms that get worse day by day belong to the list at the top of this page.
The schedule is the treatment, and the interval your doctor sets is part of it. At first, most people need injections once a month, and after that your doctor tells you how often you need injections to help stop vision loss from AMD6 That is why a missed slot is worth a phone call rather than a shrug. Book the next appointment before you leave the building. If longer gaps would make your life workable enough to actually attend, that is a fair argument to raise about Eylea HD.
Questions Patients Ask About Eylea and Eylea HD
Close, but not exactly. Eylea HD holds 8 mg of aflibercept in 0.07 mL. Eylea holds 2 mg in 0.05 mL12 So it is four times the drug in a slightly larger volume, rather than four times the injection. The active ingredient is identical. What changes is how much of it your eye receives at one sitting. That is what allows the longer gaps the HD schedules are built around.
The trials were not designed to show that, and they did not. In PULSAR and PHOTON, the 8 mg schedules produced average vision changes at one year within 4 letters of the 2 mg schedule. That was the pre-set bar for saying the higher dose was not worse910 If someone offers Eylea HD as an upgrade for sharper sight, that is a misreading. What is on offer is fewer injections for a similar result.
Often yes. It is a common conversation once an eye is steady. The American Academy of Ophthalmology's practice pattern puts the choice of biologic product with the treating ophthalmologist and the patient whenever possible5 A switch restarts the schedule at the top, because Eylea HD begins with monthly doses before the longer gaps1 Ask what your doctor will watch on your scan to judge whether the switch held.
Most people do not notice a difference. The extra volume is 0.02 mL, and the needle and technique are the same. Both injections are given after numbing medicine is put on the eye and the eye is cleaned11 Eye pain is on the Eylea label's list of reactions reported in 5 percent or more of patients, and ocular discomfort, eye pain and eye irritation are on the Eylea HD label's list of reactions reported in 3 percent or more21 A gritty eye for a day afterwards is usual with either one.
It depends on your condition and how your eye responds, so your team will confirm your own plan. For wet AMD both strengths open with three monthly doses. After that Eylea is usually every 8 weeks, while Eylea HD can be extended to every 8 to 16 weeks21 In practice that often means a few fewer visits in year one with the HD version. In PULSAR, the 8 mg groups on 12-week and 16-week intervals gained about as much vision at 48 weeks as the 2 mg group on 8-week intervals9
No, and this is the one clean difference in approved uses. Eylea 2 mg is approved for retinopathy of prematurity, at a much smaller 0.4 mg dose, with at least 10 days between doses in the same eye. Eylea HD is not approved for that use21 Newborn eye care is run by a retina or pediatric ophthalmology team on its own screening timetable. Nothing about the adult schedules on this page applies to it.
More Questions About Safety, Switching, and Cost
Call and rebook as soon as you notice. Do not wait for the next scheduled slot. Missing one appointment is not an emergency in itself, and it is not a reason to give up on the course. It does matter, though, because the interval is doing the work. After the first monthly doses, your doctor tells you how often you need injections to help stop vision loss from AMD6 Tell the clinic if travel or cost got in the way, since that changes which drug suits you.
A clot-related risk is listed on both labels. Both aflibercept labels state that there is a potential risk of arterial thromboembolic events, meaning clot-related events such as stroke or heart attack, following intravitreal use of VEGF inhibitors12 Tell your retina specialist if you have had a recent stroke or heart attack, because that is a factor they weigh. This is a discussion for the doctors who know your history, not a decision to make from a general page.
Usually it is covered for its approved uses, but plans differ and many ask for paperwork first. The practical step is to have the clinic's billing team check both options against your specific plan before your next appointment. Pavblu, an aflibercept biosimilar licensed in the US, comes at the 2 mg dose rather than the 8 mg dose12 That can make the 2 mg route cheaper for some patients. Cost is a fair thing to raise, and it changes real decisions.
Some people can and some cannot, and it is not a decision to make alone. The Eylea label describes dosing every 8 weeks after the first three monthly doses, with one dose every 12 weeks possible after one year of effective therapy, and the Eylea HD label describes every 8 to 16 weeks after three monthly doses21 Stopping is a decision to make with your retina specialist, who can keep watching your scans afterwards. If the burden is what you want to escape, ask about longer intervals first.
Bring this short list to your next appointment and write the answers on the back of your appointment card.
- Which condition are we treating, in which eye, and what are we trying to hold on to?
- Would the 8 mg dose let me stretch my interval, and what would you watch on my scan to decide?
- How many injections should I plan for over the next year?
- What does each option cost me under my plan, and is a biosimilar an option here?
- What number do I call after hours, and which symptoms mean I use it the same day?
- Is there anything in my history, such as a recent stroke or eye inflammation, that favors one option?
- U.S. prescribing information for aflibercept 8 mg (FDA label via DailyMed, U.S. National Library of Medicine) (2026). EYLEA HD (aflibercept) injection, for intravitreal use: full prescribing information.
- U.S. prescribing information for aflibercept 2 mg (FDA label via DailyMed, U.S. National Library of Medicine) (2024). EYLEA (aflibercept) injection, for intravitreal use: full prescribing information.
- Clinical Ophthalmology (Kiss S, et al.) (2018). Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.
- Epidemiology and Health (Mun Y, et al.) (2021). Real-world incidence of endophthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology.
- American Academy of Ophthalmology (2026). Age-Related Macular Degeneration Preferred Practice Pattern (2024, updated 2026).
- National Eye Institute (NIH) (2024). Treatments for Wet AMD (Advanced Neovascular AMD).
- Cochrane Database of Systematic Reviews (Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS) (2019). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration (Cochrane systematic review).
- National Eye Institute (NIH) (2024). Macular Edema.
- The Lancet (PubMed 38461841) (2024). Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
- The Lancet (PubMed 38461843) (2024). Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
- National Eye Institute (NIH) (2024). Injections to Treat Eye Conditions.
- FDA label via DailyMed (U.S. National Library of Medicine) (2026). PAVBLU (aflibercept-ayyh) injection, for intravitreal use: prescribing information.